View all: Case Studies
Dr Holly Butler
University of Strathclyde
Converge Challenge 2017 Runner up
ClinSpec Dx, a spin-out from the University of Strathclyde is pioneering a new blood test that can detect brain tumors rapidly, allowing for early diagnosis.
Co-founded by Dr Holly Butler, a postdoctoral research associate at the University of Strathclyde, the company uses revolutionary technology to provide accurate results in minutes.
With proof-of-concept and commercial / health viability tests complete, ClinSpec Dx is now undergoing diagnostic accuracy studies at Western General Hospital, Edinburgh, with an anticipated roadmap to commercial launch in 2021.